Company profile
Apollomics Inc.
NASDAQ:APLMBiotechnology: Pharmaceutical Preparations
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| VEBRELTINIB | phase1 | — | 1 | unknown |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (5)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT05367388 | phase1 | unknown | 2022-05-20 | 2022-11-01 | Apollomics Inc. | A Study Comparing Two Different Capsules, APL-101 and PLB-1001 Capsules, in Healthy Chinese and Caucasian Participants |
| NCT03175224 | phase2 | recruiting | 2017-09-27 | 2026-03-30 | Apollomics Inc. | APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors |
| NCT05055518 | phase1 | suspended | 2021-08-02 | 2028-10-31 | Apollomics Inc. | APL-102 Capsule in Patients With Advanced Solid Tumors |
| NCT04839341 | phase1 | completed | 2021-02-24 | 2024-06-28 | Apollomics Inc. | Study to Evaluate PK and Safety With Uproleselan Combined With Chemotherapy to Treat Chinese R/R AML Patients |
| NCT05054543 | phase3 | terminated | 2021-11-17 | 2024-08-22 | Apollomics Inc. | Study to Evaluate the Efficacy of Uproleselan in Combination With Chemotherapy in Chinese Patients With R/R AML |
FDA applications (0)
No records yet.